Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Biomarkers of response to molecular targeted therapy in renal cell carcinoma].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Jul 2011

Mizuno Ryuichi, Oya Mototsugu

Abstract excerpt

Therapeutic options for metastatic renal cell carcinoma (mRCC) have been evolving rapidly, with the approval of a variety of effective molecular targeted agents. With increasing choices of treatment modalities that may potentially improve survival, it is of great clinical benefit to be able to predict the clinical outcome of mRCC patients treated with molecular targeted agents. In addition, predictors of severe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Kidney Neoplasms
Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Molecular Targeted Therapy

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 21772092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Biomarkers of response to molecular targeted therapy in renal cell carcinoma].PMID 21772092Read ↗

Molecular biomarkers in advanced renal cell carcinoma.Semantic proximity Read ↗

Molecular markers to predict response to therapy.Semantic proximity Read ↗

Kidney cancer pathology in the new context of targeted therapy.Semantic proximity Read ↗

From bench to bedside: current and future applications of molecular profiling in renal cell carcinomaSemantic proximity Read ↗

A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Semantic proximity Read ↗

The amount of circulating DNA and the presence of TP53 mutations in plasma predict clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsSemantic proximity Read ↗

Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.Semantic proximity Read ↗

VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.Semantic proximity Read ↗

Prognostic and predictive biomarkers in renal cell carcinoma.Semantic proximity Read ↗

Biomarkers in renal cancer.Semantic proximity Read ↗

Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-CarcinomaSemantic proximity Read ↗

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.